Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials

The recent development of monoclonal antibodies targeted to proprotein convertase subtilisin/kexin type 9 (PCSK9), e.g., PCSK9 inhibitors has revolutionized the landscape of lipid management. Many clinical trials assessing this class have demonstrated remarkable and consistent reductions in low-dens...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Front Cardiovasc Med
Main Authors: Wong, Nathan D., Shapiro, Michael D.
Format: Artigo
Sprog:Inglês
Udgivet: Frontiers Media S.A. 2019
Fag:
Cardiovascular Medicine
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6414420/
https://ncbi.nlm.nih.gov/pubmed/30895178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcvm.2019.00014
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker